Candida Pelliculosa Fungemia Cases in Pediatric Intensive Care Unit

Otağ, Feza; Yarpuzlu, Mehmet; Gülbudak, Harun; Arslanköylü, Ali Ertuğ; Fouad, Ali; Emekdaş, Gürol

doi:10.5152/ced.2015.1662

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite being uncommon, the role of this pathogen causing outbreaks has been reported in children. 4,15,29,30 Similarly, C. glabrata in another study has reported increase from 2.6% in 2003 to 23.7% in 2012. 12 There were significant differences in Candida spp.…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Candidemia in a Pediatric Population: A 10-year Indian Study

Adhikary¹,

Venkatesh²,

Joshi³

et al. 2021

Pediatric Infectious Disease

View full text Add to dashboard Cite

Introduction: Candidemia has emerged as one of the life-threatening causes of invasive infection in both adults and children worldwide. Materials and methods: We performed a retrospective study of children (≤16 years) with candidemia diagnosed in our center in 2010 to 2019. Demographics, comorbidities, Candida species distribution, antifungal susceptibility, and outcomes were analyzed. Results: A total of 96 children were identified in the last 10 years. The predominant species identified were C. tropicalis (23%), C. parapsilosis (15.6%), C. pelliculosa (15.6%), C. albicans (13.6%), C. krusei (7.3%), and C. haemulonii (5.2%). Male to female ratio was 2:1. The most common risk factor was found to be congenital malformations (27%), followed by hematological malignancy in 13.5%. Candidemia was diagnosed while being admitted in the intensive care unit in 74%, 14.5% in wards, and 11.5% in outpatients. The overall mortality rate was found to be 31.3%. C. tropicalis was found to be sensitive to fluconazole in 95.5%, flucytocine in 95.2%, and 100% susceptible to amphotericin B, voriconazole, and caspofungin. Conclusion:Invasive candidiasis occurs frequently in hospitalized patients and is associated with high mortality rates. C. tropicalis was the most frequently isolated species. We have observed a shift in Candida spp. with an increasing isolation of C. pelliculosa. The occurrence of azole resistance is a matter of concern. Clinical significance: This type of data analysis is needed to track trends of serious infection and to develop guidelines for infection control strategies and antimicrobial stewardship program.

show abstract

Section: Discussionmentioning

confidence: 86%

“…has been a global concern in recent times. 6,9,10,14,15 There has been an increase in the proportion of infections due to C. glabrata and C. parapsilosis in the last few decades. These species show higher levels of resistance to antifungal agents and therefore might be associated with higher mortality than C. albicans.…”

Section: Introductionmentioning

confidence: 99%

Candidemia in a Pediatric Population: A 10-year Indian Study

Adhikary¹,

Venkatesh²,

Joshi³

et al. 2021

Pediatric Infectious Disease

View full text Add to dashboard Cite

show abstract

“…A total of 243 articles from PubMed and Scopus were screened. Finally, 36 met the present study’s inclusion criteria [ 19 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ]. These 36 studies involved 170 patients in total.…”

Section: Resultsmentioning

confidence: 99%

Fungemia by Wickerhamomyces anomalus—A Narrative Review

Ioannou,

Baliou,

Kofteridis

2024

Pathogens

View full text Add to dashboard Cite

Wickerhamomyces anomalus has been previously classified as Hansenula anomala, Pichia anomala, and Candida pelliculosa and was recently reclassified in the genus Wickerhamomyces after phylogenetic analysis of its genetic sequence. An increasing number of reports of human infections by W. anomalus have emerged, suggesting that this microorganism is an emerging pathogen. The present review aimed to provide data on the epidemiology, antifungal resistance, clinical characteristics, treatment, and outcomes of fungemia by W. anomalus by extracting all the available information from published original reports in the literature. PubMed/Medline, Cochrane Library, and Scopus databases were searched for eligible articles reporting data on patients with this disease. In total, 36 studies involving 170 patients were included. The age of patients with fungemia by W. anomalus ranged from 0 to 89 years; the mean age was 22.8 years, the median age was 2.2 years, with more than 37 patients being less than one month old, and 54% (88 out of 163 patients) were male. Regarding patients’ history, 70.4% had a central venous catheter use (CVC), 28.7% were on total parenteral nutrition (TPN), 97% of neonates were hospitalized in the neonatal ICU (NICU), and 39.4% of the rest of the patients were hospitalized in the intensive care unit (ICU). Previous antimicrobial use was noted in 65.9% of patients. The most common identification method was the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in 34.1%, VITEK and VITEK 2 in 20.6%, and ID32 C in 15.3%. W. anomalus had minimal antifungal resistance to fluconazole, echinocandins, and amphotericin B, the most commonly used antifungals for treatment. Fever and sepsis were the most common clinical presentation noted in 95.8% and 86%, respectively. Overall mortality was 20% and was slightly higher in patients older than one year. Due to the rarity of this disease, future multicenter studies should be performed to adequately characterize patients’ characteristics, treatment, and outcomes, which will increase our understanding and allow drawing safer conclusions regarding optimal management.

show abstract